Authors
Luigino Calzetta, Paola Rogliani
Published in
Expert opinion on pharmacotherapy. Jul 14, 2026. Epub Jul 14, 2026.
Abstract
Asthma treatment has long relied on short-acting β2-adrenergic receptor (β2-AR) agonists (SABA) such as salbutamol for as-needed relief, often without concurrent anti-inflammatory therapy. Emerging data link frequent SABA use to higher exacerbation rates and mortality. Current recommendations organize asthma treatment into Track 1, with as-needed inhaled corticosteroid (ICS)/formoterol used also as maintenance-and-reliever therapy, and Track 2, with SABA or ICS/SABA reliever plus separate maintenance; Track 1 is identified as the preferred option.
This review evaluates β2-AR agonist use within the Track 1/Track 2 context. Randomized trials show as-needed ICS/formoterol reduces severe exacerbations more than SABA-based regimens, without a detectable mortality signal. Large observational evidence indicates that 3-5 SABA canisters per year already associates with increased mortality, with higher risk at 6-10 and ≥11 canisters per year. Contemporary trials and real-world studies reveal many patients on SABA-centered or fluticasone furoate/vilanterol regimens may reach these exposure levels, whereas ICS/formoterol regimens produce lower reliever use and fewer exacerbations.
Where ICS/formoterol is accessible, Track 1 should be the default strategy. Clinicians should minimize SABA overuse, prioritize ICS/formoterol regimens, and advocate policies improving access to reduce preventable morbidity and mortality.
PMID:
42444391
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0